SUBSCRIBE
SUBSCRIBE

GLP-1

Novo Nordisk A/S’s Diabetes Drug Beats Out Eli Lilly’s Trulicity in Phase III Trials
Policy
Agreement Reached After Novo Nordisk A/S is Accused of Disguising Salespeople and Dealing Kickbacks
May 1, 2017
 · 
2 min read
Drug Development
Can Psoriatic Arthritis Lift Gilead’s Sinking Ship?
April 20, 2017
 · 
1 min read
Biotech Beach
Nine Blockbuster Drugs To Watch Are Making Their Debut, Aiming At A $16B Prize In 2021
April 11, 2017
 · 
1 min read
Job Trends
A Day In The Life Of A Scientist At AstraZeneca
March 13, 2017
 · 
1 min read
Tiny KalVista Explodes on $760 Million Deal With Drug Giant Merck & Co.
Business
Tiny Boston Biotech Pieris Nabs $570 Million+ Cancer Deal With French Powerhouse Servier
January 5, 2017
 · 
2 min read
Genetown
After Rough 2016, Markets To Open For Emerging Biotech
December 14, 2016
 · 
1 min read
Merck & Co.'s Alzheimer's Contender Wows in Human Clinical Trial
Pharm Country
Why Investors Should Buy (and Avoid) Merck & Co.
November 11, 2016
 · 
2 min read
Biotech Bay
Celgene Pitted Against Gilead, Biogen In Crohn’s Drug Battle
October 19, 2016
 · 
1 min read
BioMidwest
ImageQuantify.com Announces New IQbot For Quantitative Image Analysis Of Eotaxin
September 22, 2016
 · 
2 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Drug Development
Gilead Terminates Phase II/III Study of Ulcerative Colitis Drug
September 21, 2016
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China
February 11, 2026
 · 
4 min read
Press Releases
Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide
February 10, 2026
 · 
8 min read
Press Releases
Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
February 4, 2026
 · 
9 min read
Press Releases
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
February 3, 2026
 · 
6 min read
Press Releases
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
February 1, 2026
 · 
8 min read
Press Releases
LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
January 30, 2026
 · 
5 min read
Press Releases
BetterWay Launches GLP-1 Blood Testing Panel at Retail Locations in Austin and Temple
January 30, 2026
 · 
2 min read
Press Releases
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
January 29, 2026
 · 
8 min read
Press Releases
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
January 28, 2026
 · 
3 min read
Press Releases
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
January 28, 2026
 · 
3 min read
Press Releases
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
January 28, 2026
 · 
3 min read
Press Releases
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
January 27, 2026
 · 
4 min read
Press Releases
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
January 27, 2026
 · 
6 min read
Press Releases
Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
January 26, 2026
 · 
4 min read
Press Releases
CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist
January 23, 2026
 · 
3 min read
Press Releases
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
January 20, 2026
 · 
4 min read
Press Releases
RO ANNOUNCES RESEARCH COLLABORATION TO BETTER UNDERSTAND AND IMPROVE THE REAL-WORLD PATIENT EXPERIENCE WITH GLP-1S
January 13, 2026
 · 
2 min read
Press Releases
Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)
January 13, 2026
 · 
6 min read
Press Releases
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
January 12, 2026
 · 
8 min read
Press Releases
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
January 9, 2026
 · 
6 min read
Load More